Risk of suicide and SSRIs.
The controversy surrounding the use of Selective Serotonin Reuptake Inhibitors (SSRIs), in the treatment of depression and other psychiatric disorders in children and adolescents, has come to the forefront since the question of increased suicidal risk has been raised. There are limited research data available to thoroughly analyze the safety and efficacy of this class of medications in youths. In this article, we review the evidence available, the events that led to the black box warning, and the practical implications of the warning for providers, youth and families.
Hanna
Nora
N
Child and Adolescent Psychiatry, Institute of Living/Hartford Hospital, Hartford, USA.
Karabelnik
Lisa
L
Ranga
Jyotsna
J
D000293:Adolescent; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003237:Connecticut; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D000092864:Suicide Prevention
D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors